<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574948</url>
  </required_header>
  <id_info>
    <org_study_id>2017-005059-10</org_study_id>
    <nct_id>NCT03574948</nct_id>
  </id_info>
  <brief_title>5-HTP in Patients With IBD in Clinical and Biologic Remission:Effect on Fatigue Scores</brief_title>
  <acronym>TRP-IBD</acronym>
  <official_title>Multicentric, Double-blind, Placebo Controlled Clinical Trial With 5-hydroxytryptophan (5-HTP) in Patients With Inflammatory Bowel Disease in Clinical and Biologic Remission: Effect on Fatigue Scores</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This placebo cross-over trial aims to study the effect of the oral intake of an essential
      amino-acid 5-OH tryptophan, the precursor of serotonin, on the fatigue scores in IBD patients
      in deep clinical and biological remission.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Analog Scale (VAS) after intervention</measure>
    <time_frame>weekly, 16 weeks</time_frame>
    <description>Patients are asked to indicate their fatigue level on a VAS-scale from 0 to 10, where 0 represents no fatigue and where 10 indicates the patient suffers from severe fatigue.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Functional Assessment of Chronic Illness Therapy—Fatigue (FACIT-F) score</measure>
    <time_frame>week 0, week 8 and week 16</time_frame>
    <description>The questionnaire is a self-assessment that need to be completed without external help. The FACIT-F questionnaire measures the fatigue of the patient and will be filled in at week 0, week 8 and week 16. The FACIT Fatigue scale ranges from 0 to 52, with high scores indicating higher levels of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in short Depression Anxiety and Stress Scale (DASS21)</measure>
    <time_frame>week 0, week 8 and week 16</time_frame>
    <description>The questionnaire is a self-assessment that need to be completed without external help. The DASS questionnaire measures depression and anxiety and will be filled in at week 0, week 8 and week 16. The questionnaire contains 7 items per scale, the maximum score for depression, anxiety and stress will be 21. The higher the score of the questionnaire, the more the patient suffers from depression, anxiety and stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Adapted International Physical Activity Questionnaire (IPAQ)</measure>
    <time_frame>week 0, week 8 and week 16</time_frame>
    <description>The adapted IPAQ questionnaire measures the physical activity and will be filled in at week 0, week 8 and week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum 5-HydroxyTryptophane (5-HTP) by treatment</measure>
    <time_frame>Week 0, week 8 and week 16</time_frame>
    <description>The possible effect of Levotonine administration on the serum 5-HTP levels will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum 5-hydroxyindoleacetic acid by treatment</measure>
    <time_frame>Week 0, week 8 and week 16</time_frame>
    <description>The possible effect of Levotonine administration on the serum 5-hydroxyindoleacetic levels will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum serotonin levels by treatment</measure>
    <time_frame>Week 0, week 8 and week 16</time_frame>
    <description>The possible effect of Levotonine administration on the serum serotonin levels will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum melatonin levels by treatment</measure>
    <time_frame>Week 0, week 8 and week 16</time_frame>
    <description>The possible effect of Levotonine administration on the serum melatonin levels will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in faecal microbiome/metabolome</measure>
    <time_frame>Week 0, week 8 and week 16</time_frame>
    <description>since the intestinal bacteria can process tryptophane, changes in the faecal microbiome/metabolome can be possibly caused by the administration of levotonine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Fatigue</condition>
  <condition>Remission</condition>
  <arm_group>
    <arm_group_label>5-HTP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 weeks active substance 5-HTP (2 x 100 mg per day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo oral capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 weeks placebo (2 x 1 capsule per day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-HTP</intervention_name>
    <description>8 weeks active substance 5-HTP (2 x 100mg per day)</description>
    <arm_group_label>5-HTP</arm_group_label>
    <other_name>Levotonine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>8 weeks placebo (2 x 1 caps per day)</description>
    <arm_group_label>placebo oral capsule</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is male or female and aged 18 to 60 yrs (inclusive)

          -  The subject has a documented Crohn's disease or ulcerative colitis

          -  The subject is, in the opinion of the investigator, capable of understanding and
             complying protocol requirements

          -  The subject is in clinical remission over last 3 months (based on physician global
             assessment)

          -  The subject is in clinical remission at day 0 based on validated scores (SCCAI ≤ 2 for
             ulcerative colitis or Harvey Bradshaw index ≤ 4 for Crohn's disease).

          -  The subject reports fatigue on a quantified scale (visual analogue scale 0 - 10) of 5
             or more

          -  The subject is treated with biologicals and/or immunosuppressives since at least 6
             months with stable dose over last 3 months

          -  The subject is in biologic remission at day 0: CRP &lt; 10 mg/l and faecal calprotectin
             value &lt; 250 mg/kg

        Exclusion Criteria:

          -  The subject has a clinical validated depression

          -  The subject is taking antidepressives or neuroleptics

          -  The subject has a psychiatric comorbidity

          -  The subject has important comorbidities: cardiovascular disease, obstructive lung
             pathology, neoplasia or other

          -  The subject has a documented Anemia (based on lab results including Hb &lt; 12-13 g/dl
             respectively for saturation index &lt; 20%, Vit B12 &lt; 148 pmol/L or folic acid &lt; 6
             nmol/L)

          -  The subject has a documented hypothyreoidea (documented by a recent lab result
             including TSH)

          -  The subject reports an infection within 2 weeks before inclusion

          -  The subject reports any change in IBD medication (biologicals and immunosuppressives)
             in the last 12 weeks before inclusion

          -  The subject was treated with oral corticosteroids during the last 8 weeks before
             enrolment

          -  The subject reports an ongoing pregnancy or breastfeeding

          -  The subject has a history of lymphoproliferative disease or cancer other than
             basocellular skin cancer

          -  The subject underwent surgery in the past 12 weeks prior to the screening visit

          -  The subject reports a history of clinically significant drug abuse (defined as any
             illicit drug use) or alcohol abuse within 1 year prior to inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martine De Vos, MD, PhD</last_name>
    <phone>0032 9 332 23 71</phone>
    <email>martine.devos@uzgent.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Triana Lobaton Ortega, MD, PhD</last_name>
    <phone>0032 9 332 23 89</phone>
    <email>Triana.LobatonOrtega@UZGENT.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Imelda</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Bossuyt, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peter Bossuyt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ULB Erasme</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Franchimont, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Denis Franchimont, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Pièrre</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinciane Muls, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vinciane Muls, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL Saint-Luc</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Dewit, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier Dewit, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien Kindt, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sebastien Kindt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine De Vos, MD, PhD</last_name>
      <phone>+32 9 332 23 71</phone>
      <email>martine.devos@uzgent.be</email>
    </contact>
    <contact_backup>
      <last_name>Triana Lobaton Ortega, MD, PhD</last_name>
      <phone>+32 9 332 23 89</phone>
      <email>Triana.LobatonOrtega@UZGENT.be</email>
    </contact_backup>
    <investigator>
      <last_name>Martine De Vos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Triana Lobaton Ortega, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pieter Hindryckx, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter Dewint, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pieter Dewint, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Lucas</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Peeters, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Harald Peeters, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Ferrante, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Marc Ferrante, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edouard Louis, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Edouard Louis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Namur</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Francois Rahier, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Francois Rahier, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Damiaan</name>
      <address>
        <city>Oostende</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Lambrecht, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guy Lamrecht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Holvoet, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

